Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.67 |
| ▸ | FLT3 | P36888 | 6/20 | 0.64 |
| ▸ | CSF1R | P07333 | 5/20 | 0.64 |
| ▸ | FLT1 | P17948 | 5/20 | 0.64 |
| ▸ | FLT4 | P35916 | 5/20 | 0.64 |
| ▸ | LYN | P07948 | 4/20 | 0.64 |
| ▸ | KIT | P10721 | 4/20 | 0.64 |
| ▸ | BLK | P51451 | 4/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | STK3 | Q13188 | 2/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | MET | P08581 | 2/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873323 | 0.91 | KDR (0.68) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3842676 | 0.90 | AURKB (0.52) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3843603 | 0.89 | KDR (0.52) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3846825 | 0.88 | KDR (0.52) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL4232674 | 0.88 | KDR (0.82) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3844772 | 0.87 | MAPT (0.52) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3852682 | 0.87 | KIT (0.66) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3845512 | 0.87 | KDR (0.50) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3845215 | 0.85 | KDR (0.66) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL13873376 | 0.82 | KDR (0.53) | KDRFLT3CSF1RFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125808-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-02 | — | — | EP | claimed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | claimed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | claimed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008071456-A2 | 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | KDR 1/4885FLT3 143/4885CSF1R 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.